<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02860845</url>
  </required_header>
  <id_info>
    <org_study_id>DOBO-01-16</org_study_id>
    <nct_id>NCT02860845</nct_id>
  </id_info>
  <brief_title>Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections</brief_title>
  <acronym>DOBO</acronym>
  <official_title>Multicenter Pilot Study to Compare the Efficacy of a Combination of Vaginal Capsules With Acid Boric, L.Gasseri and L.Rhamnosus Versus the Reference Medication in Patients With Vaginal Candidiasis or Bacterial Vaginosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Ordesa</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clever Instruments S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Laboratorios Ordesa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a formula of boric acid and probiotics for
      vaginal application is effective in the treatment of symptomatic episodes of vulvovaginitis
      in comparison to pharmacological reference controls (depending on the suspected diagnosis).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicentre, Open, Prospective, Randomized, Controlled. Women with suspected vaginal
      infection will be randomized and distributed into two groups (control or boric acid +
      probiotics). Follow-up will last for three months and consists in 3 visits and a telephone
      interview.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the presence of vaginitis clinical symptoms determined by Sobel Score.</measure>
    <time_frame>Baseline and at 2 weeks after treatment finalization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the level of lactobacillus in vaginal flora determined by vaginal cultures.</measure>
    <time_frame>Baseline and 2 weeks after treatment finalization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of recurrent infections rate determined by medical evaluation of clinical symptoms.</measure>
    <time_frame>At 3 months after recruitment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Candidiasis</condition>
  <condition>Vaginosis, Bacterial</condition>
  <arm_group>
    <arm_group_label>Boric acid and probiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotic/Antifungal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Boric acid and probiotics</intervention_name>
    <description>Vaginal capsules administered once a day during 7 days.</description>
    <arm_group_label>Boric acid and probiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotic (Clindamycin)</intervention_name>
    <description>Vaginal capsules containing a reference antibiotic (when bacterial vaginosis is suspected) administered once a day during 3 days.</description>
    <arm_group_label>Antibiotic/Antifungal</arm_group_label>
    <other_name>Clindamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antifungal (Clotrimazole)</intervention_name>
    <description>Vaginal capsules containing a reference anti-fungal (when candidiasis is suspected) administered once a day during 6 days.</description>
    <arm_group_label>Antibiotic/Antifungal</arm_group_label>
    <other_name>Clotrimazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18 years and agreement to participate by signing the consent form.

          -  Women with clinical manifestations of acute infectious vulvovaginitis (burning,
             pruritus, erythema, oedema, and abnormal vaginal discharge).

        Exclusion Criteria:

          -  Clinical findings compatible with Chlamydia trachomatis, Neisseria gonorrhoeae or
             Trichomonas vaginalis infection.

          -  Use of anti-fungal, antibiotic or probiotic medication within last 2 weeks prior to
             the study.

          -  Patients receiving other treatment (drug, probiotics or vitamin supplements) that can
             significantly interfere with study evaluations during the 3 months of follow-up.

          -  Pregnant or high risk for pregnancy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan A Tena, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ginemed Sevilla</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mireia Morera</last_name>
    <email>mireia.morera@ordesa.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marta Guarro</last_name>
    <email>marta.guarro@ordesa.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ginemed Sevilla</name>
      <address>
        <city>Sevilla</city>
        <state>Andaluc√≠a</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan A Tena, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2016</study_first_submitted>
  <study_first_submitted_qc>August 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2016</study_first_posted>
  <last_update_submitted>August 4, 2016</last_update_submitted>
  <last_update_submitted_qc>August 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Vaginal Diseases</mesh_term>
    <mesh_term>Vaginosis, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Miconazole</mesh_term>
    <mesh_term>Antifungal Agents</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

